O

Outlook Therapeutics
D

OTLK

1.57000
USD
-0.06
(-3.68%)
مغلق
حجم التداول
15,301
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
50,266,971
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ACAD
    -0.350
    (-1.73%)
    19.940 USD
    A
    ARWR
    -1.040
    (-4.97%)
    19.900 USD
    A
    AXSM
    8.550
    (6.62%)
    137.720 USD
    C
    CRVS
    -0.22000
    (-4.99%)
    4.19000 USD
    I
    IMMP
    -0.06000
    (-3.03%)
    1.92000 USD
    V
    VKTX
    2.480
    (7.85%)
    34.090 USD
    المزيد
الأخبار
المقالات

العنوان: Outlook Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorizationfor an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.